Zidovudine
- Generic Name
- Zidovudine
- Brand Names
- Combivir, Retrovir, Trizivir
- Drug Type
- Small Molecule
- Chemical Formula
- C10H13N5O4
- CAS Number
- 30516-87-1
- Unique Ingredient Identifier
- 4B9XT59T7S
- Background
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
- Indication
Used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.
- Associated Conditions
- HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Perinatal HIV transmission
- Associated Therapies
- -
The Safety and Effectiveness of MK-639 and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 780
- Registration Number
- NCT00002443
A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pharmacia and Upjohn
- Target Recruit Count
- 1250
- Registration Number
- NCT00002124
- Locations
- 🇺🇸
CARE Ctr / UCLA Med Ctr, Los Angeles, California, United States
🇺🇸Los Angeles County - USC Med Ctr, Los Angeles, California, United States
🇺🇸Los Angeles County / Health Research Assoc / Drew Med Ctr, Los Angeles, California, United States
A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cell
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT00002323
- Locations
- 🇺🇸
Johns Hopkins Hosp, Baltimore, Maryland, United States
🇺🇸Northwestern Univ Med School, Chicago, Illinois, United States
🇺🇸Univ TX Galveston Med Branch, Galveston, Texas, United States
3TC (Lamivudine; GR109714X) Open-Label Program
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00002108
- Locations
- 🇺🇸
Kern - McNeill International, Morristown, New Jersey, United States
A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- HEM Research
- Registration Number
- NCT00002269
- Locations
- 🇺🇸
Miami Veterans Administration Med Ctr, Miami, Florida, United States
🇺🇸Oregon Health Sciences Univ, Portland, Oregon, United States
🇺🇸MCP Hahnemann Univ Hosp, Philadelphia, Pennsylvania, United States
The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take Zidovudine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pharmacia and Upjohn
- Registration Number
- NCT00002312
- Locations
- 🇺🇸
Bronson Methodist Hosp / Upjohn Research Clinic, Kalamazoo, Michigan, United States
A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00002046
- Locations
- 🇺🇸
Univ TX Galveston Med Branch, Galveston, Texas, United States
🇺🇸Johns Hopkins Hosp, Baltimore, Maryland, United States
🇺🇸Northshore Hosp / Cornell Univ, Manhasset, New York, United States
A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 400
- Registration Number
- NCT00002208
- Locations
- 🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸Johns Hopkins Hosp, Baltimore, Maryland, United States
🇺🇸Univ of Alabama at Birmingham, Birmingham, Alabama, United States
A Phase II/III Study of Cysteamine (Mercaptoethylamine) and Zidovudine for the Treatment of HIV Disease
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Mylan Laboratories
- Target Recruit Count
- 300
- Registration Number
- NCT00002110
- Locations
- 🇺🇸
Independent Research Nurses Inc, Cranston, Rhode Island, United States
🇺🇸Infectious Disease Research Institute Inc, Tampa, Florida, United States
🇺🇸Tulane Univ Med School, New Orleans, Louisiana, United States
A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Dupont Merck
- Registration Number
- NCT00002410
- Locations
- 🇺🇸
Bach and Godofsky, Bradenton, Florida, United States
🇺🇸Oasis Clinic / Martin Luther Jr Gen Hosp / King-Drew Med Ctr, Los Angeles, California, United States
🇺🇸Remington-Davis Inc, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.